Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) was the recipient of a large drop in short interest in November. As of November 30th, there was short interest totalling 6,457,835 shares, a drop of 12.2% from the November 15th total of 7,354,475 shares. Currently, 5.0% of the company’s stock are sold short. Based on an average daily volume of 1,127,531 shares, the days-to-cover ratio is currently 5.7 days.

Shares of Protalix Biotherapeutics (NYSEAMERICAN PLX) opened at $0.64 on Tuesday. Protalix Biotherapeutics has a 12 month low of $0.26 and a 12 month high of $1.51.

Protalix Biotherapeutics (NYSEAMERICAN:PLX) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). The business had revenue of $7.53 million during the quarter, compared to analysts’ expectations of $6.65 million. During the same period in the previous year, the business posted ($0.07) EPS.

A number of equities research analysts have weighed in on PLX shares. Zacks Investment Research upgraded Protalix Biotherapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research note on Tuesday, October 24th. BidaskClub lowered Protalix Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 2nd. Finally, HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Protalix Biotherapeutics in a research note on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $3.00.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. OxFORD Asset Management LLP acquired a new stake in Protalix Biotherapeutics during the 2nd quarter valued at approximately $576,000. Virtu KCG Holdings LLC bought a new position in Protalix Biotherapeutics during the 2nd quarter worth approximately $591,000. Finally, Renaissance Technologies LLC lifted its holdings in Protalix Biotherapeutics by 302.1% during the 1st quarter. Renaissance Technologies LLC now owns 1,927,500 shares of the company’s stock worth $2,621,000 after buying an additional 1,448,200 shares during the last quarter.

TRADEMARK VIOLATION WARNING: “Protalix Biotherapeutics Inc (PLX) Short Interest Update” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/12/protalix-biotherapeutics-inc-plx-short-interest-update-2.html.

About Protalix Biotherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.

Receive News & Ratings for Protalix Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.